Medical Licensing (MD/DO) · Independent exam preparation
European Board Examinations in Urology: Standard FEBU Preparation Guide Study Guide
Practise urgent urological decisions, interpret diagnostic findings and distinguish management options across all ten ETR domains with 60 concepts and 20 questions.
By CertMedbry · Updated 19 October 2026
Practise recognising infected obstruction, interpreting pressure-flow studies, selecting cancer investigations and protecting renal and reproductive function. This selective guide develops 60 concepts across all ten theoretical knowledge domains of the European Training Requirements in Urology, Version 2026, UEMS 2026.16. The official ETR and EBU's stated coverage of all urological topics and basic science define the full preparation scope; these concepts do not exhaust it. Clinical recommendations are supported by the relevant professional guidance.
Try 20 free practice questionsWhat is the exam format?
Check the question types, timing and outline before planning your revision.
Which examination and pathway does this guide cover?
It covers the standard European Board Examinations in Urology, comprising Part 1 Written and Part 2 Oral. The listing label 'European Board of Urology (EBU) Examination' refers to this assessment rather than a separate examination. The In-Service Assessment and FEBU International are separate pathways; their eligibility and format should not be inferred from this guide.
EBU — Fellow of the EBU (FEBU) · EBU — FEBU Part 1 Written Exam
What qualification does FEBU provide, and who is eligible?
FEBU is an added specialist qualification, not a licence to practise. General eligibility for the standard pathway concerns final-year residents and certified urologists trained or certified in an EBU member country. For the published 2026 Part 1 session, residents must be enrolled in an officially recognised national urology programme in an EBU member country and complete training by October 2027. Certified urologists must hold a national specialist qualification in urology issued in an EBU member country and be registered on the relevant national specialist register. National co-organised examinations may apply different criteria; national licensing requirements remain separate.
EBU — Fellow of the EBU (FEBU) · Important information Part 1 Written Exam | EBU
How many questions are in Part 1, and what item style is verified?
Part 1 contains 110 single-correct-answer MCQs covering the entire range of urological topics, including basic science. EBU does not specify a separate scored-versus-pretest item breakdown on the cited format page. The four-option questions here are independent single-best-answer learning drills.
How is Part 1 delivered, and is it adaptive?
EBU describes a web-based examination delivered with Televic through assessmentQ and fully supervised by an online invigilator. The published 2026 session is remote and closed book. The issuer does not describe adaptive delivery on the cited pages.
EBU — FEBU Part 1 Written Exam · Important information Part 1 Written Exam | EBU
What duration, passing score and marking rules are verified?
For the session on 12 November 2026, EBU publishes a 14:30–16:30 Central European Time examination window, giving two hours. This timing is session-specific. EBU applies cohort-based standard setting using the cohort's average score and standard deviation, with no negative marking. The cited issuer information does not establish a fixed passing percentage; the published average success rate is not a pass mark.
EBU — FEBU Part 1 Written Exam · Important information Part 1 Written Exam | EBU
Which outline applies, and are domain percentages published?
The issuer-linked outline is the European Training Requirements in Urology, Version 2026, UEMS 2026.16. It is a postgraduate training outline with a non-exhaustive knowledge section, not a percentage-weighted examination blueprint. No numerical examination-domain weights or separate examination implementation date are established by the cited outline information. Coverage allocations in this guide are editorial.
EBU — European Training Requirements · European Training Requirements in Urology — Version 2026, UEMS 2026.16 · UEMS — European Training Requirements
What is verified about Part 2 and the interval between parts?
In its Part 2 description current on 19 October 2026, EBU specifies four clinical cases reflecting everyday urological practice, assessed by two urologists over approximately 60 minutes. Assessment concerns diagnosis, judgement and decision-making; the issuer describes the mark as considering written and oral scores. The interval between Part 1 Written and Part 2 Oral may not exceed five years. Passing Part 2 in the standard pathway leads to the FEBU diploma and title.
EBU — Fellow of the EBU (FEBU) · FEBU Part 2 Oral Exam | EBU
Does the FEBU title require revalidation?
Candidates passing Part 2 from 2025 onward receive a diploma valid for five years, subject to revalidation. The issuer describes lifelong learning and registration of 200 CME credits in the EU-ACME database over five years as the basis of that process.
How should this selective guide fit into preparation?
Use it to practise clinical discrimination across every knowledge domain, then expand against the complete official ETR. EBU recommends current textbooks and EAU guidelines. The training outline establishes scope; clinical guideline chapters support management decisions. The guide, questions and flashcards deliberately give additional space to functional urology, stone disease and malignancies without claiming an official weighting.
EBU — FEBU Part 1 Written Exam · European Training Requirements in Urology — Version 2026, UEMS 2026.16
An independent preparation resource for the standard FEBU pathway at postgraduate urology specialist level. The 20 original MCQs and 20 flashcards support learning; they are not official examination items or a prediction of examination success.
Outline used: Current issuer-linked European Training Requirements in Urology, Version 2026, UEMS 2026.16, reviewed on 2026-10-10. This is the official training knowledge outline, rather than a percentage-weighted examination blueprint. No separate examination effective date was established. The workbook label 'European Board of Urology (EBU) Examination' maps to the official European Board Examinations in Urology, comprising Part 1 Written and Part 2 Oral; the assigned slug is preserved.
60 key concepts: understand, apply and avoid the traps
Work through the questions by exam domain. Explain the answer in your own words, try the example, then check the common pitfall.
Professionalismnot stated
1.How should an informed refusal of treatment be handled?
A patient with decision-making capacity may refuse recommended care after understanding its purpose, benefits, material risks and alternatives. The clinician should establish understanding and voluntariness, explore concerns and explain the likely consequences of declining treatment. A decision that appears medically unwise does not by itself establish incapacity. Respecting refusal includes offering acceptable alternatives, documenting the discussion and preserving access to continuing care rather than treating disagreement as abandonment.
Apply it
A patient understands that an obstructing tumour may damage renal function but declines surgery because preserving independence matters most. Clarify alternatives and consequences, document the informed refusal and agree on symptom management and review.
Common pitfall: Family agreement does not override the informed refusal of a capable adult. Pressure to secure consent can undermine the voluntariness that makes consent valid.
2.When can emergency treatment proceed without prior consent?
Emergency intervention may proceed when the patient cannot participate in decision-making, no representative is readily available and delay would compromise the patient's interests. Known preferences still matter; urgency does not erase a clear applicable refusal. When capacity is limited or fluctuating, involve the patient as far as possible and work with an appropriate representative. Once the patient regains capacity, obtain informed consent for further interventions rather than assuming the emergency authorisation continues indefinitely.
Apply it
An unconscious patient with a life-threatening urological emergency has no immediately available representative and no known treatment refusal. Provide necessary emergency care, record the circumstances and discuss further treatment when capacity returns.
Common pitfall: Convenience, a busy operating list or a communication barrier does not create emergency authority. First distinguish inability to communicate from inability to decide.
3.Which information can be shared with relatives?
Confidentiality applies to diagnosis, investigations and treatment, including after death. Relatives do not automatically acquire access because they provide support or ask directly. Establish the patient's preferences and permission before disclosure. Necessary communication within the clinical team should remain proportionate to care needs. Exceptional disclosure without consent requires a significant overriding obligation, consideration of alternatives and restriction to the minimum necessary information, recipients and duration, alongside applicable national requirements.
Apply it
A patient's sibling requests the result of a prostate biopsy before the patient has discussed disclosure. Confirm the patient's wishes privately and arrange an authorised discussion instead of assuming that family involvement permits access.
Common pitfall: A relative's concern is understandable but does not itself authorise disclosure. Conversely, confidentiality should not prevent necessary, appropriately limited communication within the treating team.
4.How do patient priorities shape a defensible treatment recommendation?
Shared decisions combine clinical evidence with the patient's goals, circumstances and tolerance of harm. Explain what each reasonable option is intended to achieve and which outcomes remain uncertain, then check understanding. A recommendation should identify the benefit-harm balance for that individual rather than simply listing procedures. Financial or institutional interests must not distort professional judgement; relevant unavoidable conflicts should be declared and managed before the patient makes a choice.
Apply it
Two technically suitable renal cancer operations have different functional consequences. Discuss cancer control, complication risks and kidney preservation, then ask how the patient values avoiding future renal impairment relative to the immediate surgical burden.
Common pitfall: Offering a menu without explaining trade-offs transfers the clinician's responsibility to the patient. Shared decision-making still requires an evidence-based recommendation and honest uncertainty.
Basic science and general urologynot stated
8.How do autonomic receptors explain different LUTS drug effects?
Parasympathetic acetylcholine stimulates detrusor muscarinic receptors. M2 receptors are more numerous, but M3 receptors are functionally more important for contraction. Noradrenaline acting at prostatic alpha-1 receptors increases smooth-muscle tone. Antimuscarinics and alpha-blockers therefore act on different physiological targets. Muscarinic receptors in salivary tissue also explain dry mouth during antimuscarinic treatment.
Apply it
Urgency treatment causing dry mouth suggests muscarinic blockade; reduced prostatic tone follows alpha-1 blockade. Apply this receptor physiology to functional-urology treatment selection.
Common pitfall: The most abundant receptor subtype need not mediate the dominant contractile effect. M2 predominance does not make M2 the principal detrusor contraction receptor.
9.Why do cooling and short cold ischaemia both matter?
Cooling reduces cellular metabolic demand during organ preservation, slowing depletion of energy stores and accumulation of metabolic products. It does not abolish ischaemic injury, so cold ischaemia should still be minimised. Preservation solutions help limit cell swelling, maintain electrolyte gradients and buffer acidosis; reperfusion introduces additional oxidative injury. Donor characteristics, preceding warm ischaemia and cold storage must be assessed together.
Apply it
A correctly cooled donor kidney still faces avoidable implantation delay. Expedite implantation because reduced metabolic demand does not eliminate ischaemic injury.
Common pitfall: Cold preservation slows cellular injury; it does not maintain normal metabolism or eliminate reperfusion injury.
Urological infections, STIs and parasitic diseasenot stated
10.When should catheter-associated asymptomatic bacteriuria be left untreated?
Bacteriuria in a patient with a long-term urinary catheter commonly represents colonisation rather than symptomatic infection. In the absence of attributable symptoms, routine screening and antibiotic treatment are not recommended. Pyuria does not independently establish infection requiring treatment. Repeated attempts to sterilise catheter urine expose the patient to adverse effects and antimicrobial resistance without addressing the catheter-associated state. First establish whether there are clinical features of infection or a specific treatment exception.
Apply it
A comfortable, afebrile patient with a long-term catheter has a positive culture obtained during an unrelated visit. With no attributable urinary or systemic symptoms and no planned traumatic endourological procedure, avoid antibiotics for the culture alone.
Common pitfall: Cloudy urine, pyuria or a resistant organism can prompt unnecessary treatment. The organism's resistance pattern does not convert asymptomatic colonisation into symptomatic infection.
11.Which urological procedures change the approach to asymptomatic bacteriuria?
Endoscopic urological procedures that breach mucosa create a risk of introducing organisms into tissue and blood. Screen for and treat asymptomatic bacteriuria before such procedures, using a preprocedural culture to guide targeted therapy. This differs from routine treatment of an asymptomatic catheterised patient. The relevant discriminator is expected mucosal trauma, as with transurethral tumour resection, rather than the broad label of any urological contact or uncomplicated catheter manipulation.
Apply it
An asymptomatic patient has bacteriuria before transurethral bladder tumour resection. Obtain susceptibility information and arrange targeted perioperative treatment because resection breaches the mucosa, even though the same culture would not automatically justify treatment during routine follow-up.
Common pitfall: Do not extend this exception automatically to uncomplicated catheter exchange or diagnostic cystoscopy. Procedural infectious risk depends on the intervention and anticipated mucosal disruption.
IDSA 2019 Guideline on Asymptomatic Bacteriuria · EAU Urological Infections — The Guideline
12.How should suspected acute bacterial prostatitis be investigated safely?
Abrupt fever, pelvic or perineal pain and voiding symptoms suggest acute bacterial prostatitis. Midstream urine culture is the key microbiological investigation, with blood cultures and blood count useful when systemic infection is suspected. Gentle examination may identify a tender prostate, but prostatic massage should be avoided because it can provoke bacteraemia and sepsis. Localisation tests involving expressed prostatic secretions belong to selected chronic presentations rather than this acutely ill clinical setting.
Apply it
A febrile man develops dysuria and marked perineal pain after instrumentation. Collect urine and appropriate blood cultures, assess systemic illness and begin treatment without attempting to express prostatic secretions from the swollen, tender gland.
Common pitfall: A technique useful for chronic bacterial localisation can be hazardous during acute infection. Do not perform vigorous massage to obtain a supposedly better specimen.
13.When should persistent infection trigger investigation for a prostatic abscess?
Persistent systemic illness despite appropriate antimicrobial therapy raises concern for a complication or an unresolved source. In prostatitis, imaging can identify an abscess; assess urinary retention and other obstructive factors as well. An organised collection may require drainage in addition to antibiotics, with management influenced by its size, accessibility and clinical response. Failure to improve should prompt reassessment of source control and microbiology rather than automatic escalation through increasingly broad antibiotics.
Apply it
A man receiving susceptibility-directed treatment for acute prostatitis remains febrile and clinically unwell. Recheck cultures and urinary drainage, and obtain imaging for an abscess rather than simply extending the same treatment without reassessment.
Common pitfall: Persistent fever does not prove antibiotic resistance. A drainable collection or obstruction can prevent recovery even when the selected antimicrobial is microbiologically active.
14.Which specimens best investigate suspected sexually transmitted urethritis?
Urethral discharge and dysuria after sexual exposure require testing directed at urethral pathogens. Validated nucleic acid amplification testing on first-void urine or a urethral specimen detects infections that routine bacterial urine culture may miss. When gonorrhoea is suspected, a urethral or meatal culture also supports antimicrobial susceptibility testing. Microscopy showing intracellular Gram-negative diplococci provides a rapid diagnostic cue, but molecular testing remains important for identifying relevant pathogens and concurrent infections.
Apply it
A man with discharge has a negative routine midstream culture. Arrange first-void urine NAAT for relevant urethral pathogens and obtain gonococcal culture when indicated, explaining why the previous culture did not exclude a sexually transmitted infection.
Common pitfall: A negative routine urine culture does not exclude urethritis. First-void sampling and pathogen-specific testing answer a different diagnostic question from standard midstream culture.
15.How is suspected genitourinary tuberculosis investigated microbiologically?
Consider genitourinary tuberculosis when persistent urinary inflammation, compatible exposure or previous tuberculosis and structural urinary abnormalities are not explained by routine bacterial testing. Investigation requires mycobacterial methods rather than assuming an ordinary negative culture excludes infection. The EAU recommends three midstream first-void urine samples on consecutive days for mycobacterial culture, with an appropriate molecular test as an adjunct. Culture remains important because molecular detection and bacterial growth provide different information.
Apply it
A patient with previous tuberculosis has persistent urinary symptoms and pyuria despite negative routine cultures. Request three appropriately collected consecutive-day urine specimens for mycobacterial culture and adjunct molecular testing rather than another empirical course for ordinary cystitis.
Common pitfall: Sterile pyuria is a clue, not a diagnosis. Stones, malignancy and other inflammatory conditions remain alternatives; a tuberculosis history should guide targeted investigation.
Functional urology, incontinence, LUTS and BPHnot stated
5.How do pressure-flow studies distinguish obstruction from weak contraction?
Urinary flow reflects both the pressure generated by the detrusor and resistance at the outlet. Low flow accompanied by high detrusor pressure supports bladder outlet obstruction; low flow with low detrusor pressure suggests detrusor underactivity. Detrusor pressure represents vesical pressure after subtracting abdominal pressure, so straining must not be mistaken for muscle contraction. This is functional-urology assessment: interpret a technically sound pressure-flow trace alongside symptoms and other findings before predicting the benefit of outlet surgery.
Apply it
Two men each void at 6 mL/s. One generates a detrusor pressure of 85 cm H2O, while the other generates 18 cm H2O. Their similar flow rates conceal different mechanisms and different surgical expectations.
Common pitfall: A slow stream alone does not establish prostatic obstruction. Treating the outlet cannot be assumed to restore an intrinsically weak detrusor contraction.
6.How is the bladder outlet obstruction index interpreted?
In male pressure-flow assessment, the bladder outlet obstruction index is detrusor pressure at maximum flow minus twice the maximum flow rate: BOOI = pdetQmax − 2Qmax. Values above 40 indicate obstruction, values from 20 to 40 are equivocal and values below 20 are unobstructed. The index classifies outlet resistance rather than symptom severity or muscle strength. Use simultaneous pressure and flow measurements, with pressure in cm H2O and flow in mL/s.
Apply it
A man has pdetQmax of 72 cm H2O and Qmax of 11 mL/s. His BOOI is 72 − 22 = 50, supporting obstruction; the calculation does not independently establish whether contractility is normal.
Common pitfall: Using the maximum pressure anywhere on the trace instead of pressure at maximum flow can misclassify obstruction. Do not substitute the contractility formula.
7.What does the bladder contractility index add?
The bladder contractility index is calculated as BCI = pdetQmax + 5Qmax. Values below 100 indicate weak contractility, 100–150 indicate normal contractility and values above 150 indicate strong contractility. BCI and BOOI answer different questions: a patient can have weak contractility and obstruction together. Recognising both components improves counselling about persistent emptying difficulty after deobstruction. These male pressure-flow indices require appropriate technical quality and should not be generalised indiscriminately to every patient group.
Apply it
With pdetQmax of 55 cm H2O and Qmax of 5 mL/s, BCI is 80 and BOOI is 45. Explain that obstruction coexists with weak contractility, so outlet relief may not normalise emptying.
Common pitfall: A low BCI does not prove that obstruction is absent. Conversely, a high BOOI does not guarantee normal muscle strength or complete postoperative recovery.
16.What can alpha-blockers achieve in male LUTS?
Alpha-blockers reduce adrenergically mediated smooth-muscle tone and can improve male lower urinary tract symptoms relatively quickly. Their symptomatic benefit should be separated from long-term modification of prostate growth: they do not shrink the prostate or reliably prevent future retention and surgery. Treatment selection therefore depends on the immediate symptom goal and the patient's progression risk. Improvement during therapy does not prove that every symptom was caused by anatomical prostatic obstruction.
Apply it
A man wants rapid relief of bothersome voiding symptoms. Discuss an alpha-blocker while explaining that symptom improvement does not provide the same long-term protection against retention as treatment directed at an enlarged prostate's androgen-dependent growth.
Common pitfall: Do not promise prevention of future retention because the urinary stream improves. Symptom relief and reduction of progression risk are separate treatment outcomes.
17.When do 5-alpha-reductase inhibitors address BPH progression?
Finasteride and dutasteride reduce conversion of testosterone to dihydrotestosterone, gradually reducing androgen-dependent prostate volume. They suit men with moderate-to-severe symptoms and increased progression risk; the EAU gives prostate volume above 40 mL as an example, not an absolute eligibility boundary. Benefits develop over months, while long-term retention and surgery risks fall. PSA typically decreases approximately 50% after six to twelve months. Once suppression is established, interpretation commonly requires approximately doubling the measured PSA for comparison with untreated thresholds, alongside assessment of the treatment course and PSA trend. An apparently normal uncorrected PSA can therefore conceal a concerning result.
Apply it
A man with a 65 mL prostate has PSA of 3 ng/mL after twelve months of dutasteride. An approximate treatment-adjusted value is 6 ng/mL; integrate this with previous values and other cancer-risk findings when deciding on investigation.
Common pitfall: Neither an unchanged untreated PSA threshold nor an expectation of immediate symptom relief is appropriate. The approximate correction is not a substitute for assessing the individual trend.
EAU Non-neurogenic Male LUTS — Disease Management · EAU Prostate Cancer — Diagnostic Evaluation
18.Which safety issues should accompany alpha-blocker counselling?
Alpha-blocker selection requires attention to blood pressure, falls, sexual priorities and planned cataract surgery. Vasodilating agents can cause dizziness and orthostatic hypotension, particularly with cardiovascular comorbidity or other vasoactive drugs. More selective agents can cause ejaculatory dysfunction. Previous or current exposure is also relevant to intraoperative floppy iris syndrome, especially with tamsulosin, so the ophthalmologist needs to know. Counselling should connect the chosen agent's adverse effects to the patient's circumstances.
Apply it
An older man taking antihypertensives reports falls and has cataract surgery planned. Review postural symptoms and medication options, coordinate with ophthalmology and explain potential ejaculatory effects before choosing an alpha-blocker for his urinary symptoms.
Common pitfall: Do not describe all agents as interchangeable simply because symptom efficacy is similar. Their vascular, ejaculatory and ophthalmic implications can change the preferred choice.
19.Why is supervised pelvic floor training first-line for female stress incontinence?
Stress incontinence is leakage associated with exertion, coughing or sneezing, reflecting inadequate continence during increased abdominal pressure. Supervised intensive pelvic floor muscle training improves the muscular support and control contributing to urethral closure. Offer a programme lasting at least three months as first-line treatment for women with stress or mixed incontinence. Supervision helps confirm effective contraction and adherence. This targets a different mechanism from medication intended primarily to reduce urgency-related bladder symptoms.
Apply it
A woman leaks during running and coughing without urgency or voiding difficulty. Offer supervised pelvic floor training for at least three months, verify her contraction technique and agree on functional goals before discussing an invasive continence procedure.
Common pitfall: A leaflet alone may not establish correct muscle recruitment. Antimuscarinic treatment is also a poor substitute when exertional leakage is the dominant mechanism.
20.How does bladder training address urgency incontinence?
Bladder training uses education, planned voiding and strategies for managing urgency to change habitual responses to bladder sensation. It is a first-line option for overactive bladder and urgency incontinence, with goals guided by a bladder diary and patient priorities. Distinguish urgency-associated leakage from exertional leakage, while recognising that both can coexist. Medication can be considered when conservative treatment is insufficient, but symptom classification and assessment of emptying remain important before adding drug therapy.
Apply it
A woman repeatedly voids pre-emptively because she fears urgency leakage, with small diary volumes and no infection. Agree on a bladder training programme and monitor urgency and leakage rather than recommending immediate surgery for stress incontinence.
Common pitfall: Frequency alone does not establish overactive bladder: high urine production can cause frequent normal-volume voids. A diary helps avoid treating the wrong mechanism.
21.Why is storage pressure central in neuro-urological management?
A neurogenic bladder can threaten renal function when filling occurs at high detrusor pressure, particularly with poor compliance or detrusor overactivity. The first treatment priority is upper urinary tract protection by establishing a safe, low-pressure reservoir. Continence is important but does not independently demonstrate safe storage. Treatment may reduce pressure while increasing residual urine, requiring a separate emptying strategy. Assess storage and emptying as related but distinct functions rather than pursuing dryness alone.
Apply it
A patient with spinal cord injury is dry between voids but develops hydronephrosis and high filling pressures. Prioritise pressure reduction and upper tract protection, while arranging an effective emptying plan and reassessment of renal risk.
Common pitfall: A dry patient can still have a dangerous high-pressure bladder. Conversely, accepting some residual urine may be necessary when reducing harmful storage pressures.
22.How should catheterisation be individualised in neurological dysfunction?
When neurological dysfunction prevents effective emptying, catheterisation decisions should incorporate bladder safety, hand function, cognition, caregiver support and patient preferences. Intermittent catheterisation is an important option, but feasibility and burden vary; technique and risks require thorough instruction. Indwelling approaches carry their own complications and should be avoided when a suitable alternative is available. The selected method must work alongside treatment of unsafe storage pressure rather than being judged solely by the residual volume.
Apply it
A patient with poor hand function cannot reliably self-catheterise, but a trained caregiver can assist. Discuss assisted intermittent catheterisation and other feasible options, considering daily support, patient preferences and the accompanying plan for safe bladder storage.
Common pitfall: Do not prescribe a technically preferred method that the patient cannot perform or sustain. Emptying the bladder also does not automatically correct high-pressure storage.
23.How can a bladder diary distinguish causes of nocturia?
A frequency-volume chart records voiding times and volumes; a fuller diary adds information such as intake, urgency and leakage. At least three representative days help identify whether nocturia accompanies increased night-time urine production, high overall production or frequent small voids. These patterns point toward different mechanisms and management options. Symptom counts alone cannot provide that distinction, and prostate enlargement should not be assumed to explain every nocturnal trip to the toilet.
Apply it
Two men report four nightly voids. One produces large night-time volumes, while the other passes repeated small amounts with urgency. Use their diaries to investigate different mechanisms before selecting the same bladder or prostate treatment for both.
Common pitfall: Counting nocturnal voids measures burden but not cause. Starting treatment from the symptom count alone can miss excess urine production or a storage problem.
Renal failure and transplantationnot stated
24.When does abrupt graft dysfunction suggest transplant arterial thrombosis?
An acute reduction in urine output with worsening graft function after transplantation requires urgent assessment of perfusion as well as drainage and haemodynamic status. Transplant renal artery thrombosis can rapidly cause graft loss; colour Doppler ultrasound is the recommended initial vascular investigation. Poor perfusion prompts surgical exploration to assess viability and possible salvage. A viable graft may permit thrombectomy, whereas a non-viable graft requires a different surgical response. Do not assume every early creatinine rise represents rejection.
Apply it
A previously functioning transplant suddenly becomes anuric shortly after surgery. Check catheter patency and haemodynamics while arranging urgent graft Doppler and transplant surgical review rather than waiting for a routine biopsy to investigate presumed rejection.
Common pitfall: Empirical treatment for rejection can delay recognition of a time-critical vascular complication. Abrupt loss of function demands a perfusion and drainage assessment.
25.How should renal impairment accompanying male LUTS be assessed?
Measure serum creatinine or eGFR when renal impairment is suspected, hydronephrosis is present or LUTS surgery is being considered. Reduced renal function warrants investigation of the kidneys and bladder, including ultrasound assessment of dilatation and residual urine. Consider hypertension and diabetes as alternative or additional causes; LUTS severity and prostate enlargement do not establish obstructive renal failure. Renal insufficiency also increases postoperative complication risk.
Apply it
A man with LUTS, diabetes and reduced eGFR needs renal and bladder assessment before attributing kidney dysfunction to BPH or promising that outlet surgery will reverse it.
Common pitfall: Symptom burden does not quantify renal impairment. A large prostate and raised creatinine can coexist without proving a causal relationship.
EAU Non-neurogenic Male LUTS — Diagnostic Evaluation · European Training Requirements in Urology — Version 2026, UEMS 2026.16
26.When does renal failure require dialysis immediately before transplantation?
Routine haemodialysis immediately before transplantation is not indicated. Assess potassium, fluid balance and acid-base disturbance; hyperkalaemia is the commonest preoperative dialysis indication. Choose dialysis or conservative correction according to the disturbance and likelihood of immediate graft function. Dialysis can delay implantation and prolong cold ischaemia, so neither automatic dialysis nor automatic omission is appropriate.
Apply it
A transplant candidate with hyperkalaemia requires correction before surgery; a stable candidate with acceptable fluid and electrolyte status does not require dialysis solely because an organ is available.
Common pitfall: The renal-failure diagnosis alone does not determine immediate dialysis timing. Balance physiological need against treatment-related delay.
EAU Renal Transplantation — The Guideline · European Training Requirements in Urology — Version 2026, UEMS 2026.16
27.What does hypothermic machine perfusion add to kidney preservation?
Hypothermic machine perfusion circulates preservation fluid through the cooled kidney and can reduce delayed graft function compared with static cold storage. Its potential value is particularly relevant to vulnerable deceased-donor organs, although outcomes depend on donor and preservation circumstances. Perfusion measurements can inform assessment but are not definitive viability tests. Increased vascular resistance or injury markers alone should not automatically justify discarding a kidney; no single machine measurement replaces integrated organ assessment.
Apply it
A team considers discarding a machine-perfused kidney solely because vascular resistance is elevated. Review donor history, ischaemic exposure and the overall assessment, recognising that this measurement predicts risk without independently proving that transplantation cannot succeed.
Common pitfall: Reduced delayed graft function is not the same as guaranteed immediate function or universal survival benefit. Avoid turning a risk marker into an absolute exclusion.
Stone diseasenot stated
28.How should sepsis with an obstructing stone be treated?
Infection behind an obstructed collecting system is a source-control emergency. Start antibiotics promptly, obtain appropriate cultures and urgently decompress with a ureteric stent or percutaneous nephrostomy according to anatomy and clinical circumstances. Both are effective drainage methods. Definitive stone fragmentation or removal should generally wait until sepsis has resolved. Antibiotics alone do not reliably address the infected obstructed compartment, while immediate definitive manipulation adds procedural burden during an unstable infectious presentation.
Apply it
A patient with fever, hypotension and hydronephrosis from a ureteric stone needs resuscitation, immediate antimicrobial treatment and urgent drainage. Plan stone clearance after infection control rather than treating the first procedure as routine definitive ureteroscopy.
Common pitfall: Stone size does not downgrade infected obstruction to uncomplicated colic. A small stone can still require emergency decompression when it obstructs an infected system.
29.Which treatment is usually preferred for renal stones larger than 20 mm?
Percutaneous nephrolithotomy is generally the primary treatment for renal stones larger than 20 mm because its clearance is less dependent on stone size than shock-wave lithotripsy or retrograde intrarenal surgery. Larger stone burdens increase the likelihood of repeated procedures and fragment-related obstruction after shock-wave treatment. Individual anatomy, bleeding risk and contraindications can change the choice, but an uncomplicated large renal stone should not be approached as though all modalities offer equivalent single-session clearance.
Apply it
A fit adult has a 28 mm renal pelvic stone, treated infection and no contraindication to percutaneous access. Discuss PCNL as the usual primary approach, including bleeding and access risks, rather than presenting repeated shock-wave sessions as equivalent.
Common pitfall: Choosing the least invasive procedure by name alone can underestimate the cumulative burden of multiple treatments. Balance invasiveness against expected clearance and complications.
30.Why can lower-pole anatomy reduce shock-wave treatment success?
Shock-wave lithotripsy must both fragment a stone and allow the fragments to leave the kidney. Lower-pole fragments may remain trapped despite adequate fragmentation, especially with a steep infundibulopelvic angle, long calyx or narrow infundibulum. Stone composition, density and skin-to-stone distance also influence success. Endoscopic or percutaneous treatment may therefore be preferable even when stone size alone appears suitable for shock waves. Distinguish a failure of fragment clearance from a failure of fragmentation.
Apply it
A patient has a lower-pole stone with a narrow, long infundibulum and an unfavourable angle. Explain why technically successful fragmentation may leave residual fragments, and compare an endoscopic option using anatomy as well as stone size.
Common pitfall: A small stone is not automatically an ideal shock-wave target. Anatomy can prevent clearance, while a resistant composition can prevent adequate fragmentation.
31.How should a specific metabolic stone evaluation be collected?
Specific metabolic evaluation uses two consecutive 24-hour urine collections to characterise daily excretion rather than relying on one spot concentration. Collection should reflect the patient's usual diet and fluid intake after recovery from the acute episode and infection. Completeness, storage and laboratory handling matter because collection errors can imitate metabolic abnormalities. Stone analysis and clinical risk assessment provide the context for selecting prevention. A sample obtained during acute illness or unusual dietary restriction may not represent habitual risk.
Apply it
A recurrent stone former collects urine while fasting after emergency treatment and misses several voids. Arrange properly instructed consecutive collections once stable and eating normally before using the results to justify long-term preventive medication.
Common pitfall: A laboratory-generated result is not necessarily a valid baseline. Incomplete collection or an atypical intake can make precise excretion values clinically misleading.
EAU Urolithiasis — Metabolic Evaluation and Recurrence Prevention
32.Why should dietary calcium usually be maintained in calcium oxalate stone formers?
Dietary calcium binds oxalate within the intestine, limiting the amount available for absorption and subsequent urinary excretion. Restricting calcium indiscriminately can therefore increase oxalate-related stone risk despite the stone's calcium content. The EAU advises normal dietary calcium, generally 1,000–1,200 mg daily, alongside attention to sodium, oxalate and fluid intake. Dietary calcium and supplements are not interchangeable: supplemental calcium has a specific role with meals in enteric hyperoxaluria rather than as a universal preventive prescription.
Apply it
A recurrent calcium oxalate stone former eliminates dairy after reading the stone report. Explain intestinal calcium-oxalate binding and restore normal dietary calcium while reviewing urine findings, excessive sodium and high-oxalate intake rather than banning all calcium.
Common pitfall: The mineral name of a stone does not directly identify the food to eliminate. Calcium restriction can shift intestinal absorption in the wrong direction.
EAU Urolithiasis — Metabolic Evaluation and Recurrence Prevention
33.How does urine volume guide fluid advice for stone prevention?
Increasing urine volume reduces the concentration of stone-forming solutes and their tendency to reach supersaturation. For general recurrence prevention, the EAU recommends sufficient fluid, preferably water, to achieve more than 2.5 L of urine over 24 hours. Required intake varies with sweating, gastrointestinal losses and other circumstances, so a fixed drinking volume does not guarantee the urinary target. Fluid advice must also account for medical conditions that limit safe intake, with individual reassessment.
Apply it
A stone former drinks 2.5 L daily but produces only 1.4 L of urine while working in heat. Use measured output and extrarenal losses to adjust the prevention plan rather than assuming the drinking target ensures adequate dilution.
Common pitfall: Fluid intake and urine output are different quantities. Giving everyone the same bottle target can overlook sweating, diarrhoea or an individual fluid restriction.
EAU Urolithiasis — Metabolic Evaluation and Recurrence Prevention
34.Why does intestinal fat malabsorption promote calcium oxalate stones?
Enteric hyperoxaluria occurs with fat malabsorption, including after some intestinal resections or malabsorptive bariatric operations. Fat-related binding of intestinal calcium leaves more oxalate available for absorption. Diarrhoeal fluid and alkali losses can add low urine volume and hypocitraturia, increasing calcium oxalate supersaturation. Prevention therefore addresses the intestinal mechanism as well as urinary chemistry: limit excessive fat and oxalate, replace fluid appropriately and consider calcium with meals to bind oxalate under an individualised plan.
Apply it
After malabsorptive surgery, a patient develops recurrent calcium oxalate stones, diarrhoea, hyperoxaluria and low urinary citrate. Address meal-related oxalate binding and intestinal losses instead of interpreting the stones as a reason to reduce calcium further.
Common pitfall: Low urinary calcium does not exclude calcium oxalate stone risk in malabsorption. High oxalate, low volume and reduced citrate can dominate the chemistry.
EAU Urolithiasis — Metabolic Evaluation and Recurrence Prevention
Urological malignanciesnot stated
35.When does a negative prostate MRI still justify biopsy?
A negative prostate MRI reduces the likelihood of clinically significant cancer but does not eliminate it. Residual risk depends on the clinical setting, particularly PSA density, examination findings, family history and previous investigations. High clinical suspicion can justify systematic biopsy despite the absence of an MRI target. Calculate PSA density by dividing PSA by prostate volume, then integrate it with the remaining evidence rather than interpreting the scan as an independent cancer exclusion test.
Apply it
A man has PSA of 12 ng/mL, a 30 mL prostate, a suspicious examination and PI-RADS 2 MRI. His PSA density is 0.40 ng/mL/cc, supporting further investigation despite the apparently reassuring scan.
Common pitfall: No visible target does not mean no significant cancer. Equally, a negative scan does not require automatic biopsy when the overall clinical suspicion is low.
36.Why is the transperineal route preferred for prostate biopsy?
Transperineal biopsy accesses the prostate through disinfected perineal skin rather than crossing rectal mucosa, reducing exposure to rectal organisms. The EAU recommends this route because of its low infectious complication risk and antibiotic stewardship advantages. Route selection is separate from deciding whether samples should be MRI-targeted, perilesional or systematic. Appropriate anaesthesia, skin preparation and consideration of individual infection risks remain necessary; a preferred route is not a guarantee that complications cannot occur.
Apply it
A patient requiring prostate biopsy asks whether MRI targeting removes the infection risk of transrectal sampling. Explain that targeting determines where tissue is taken, whereas the transperineal route changes the needle's access path and microbial exposure.
Common pitfall: Do not confuse targeting technology with the biopsy route. MRI-guided sampling can still be transrectal, and infection prevention remains relevant with either approach.
37.What makes active surveillance an active cancer strategy?
Active surveillance defers treatment toxicity while retaining curative intent, usually for suitable low-risk localised cancer with life expectancy above ten years. Assess health and comorbidity individually. Follow-up includes PSA at least every six months, clinical assessment and repeat biopsy generally every two to three years. PSA doubling time below three years prompts MRI and repeat biopsy; treatment change generally depends on biopsy progression. Selected low-risk patients with stable repeat MRI and stable PSA density below 0.15 ng/mL/cc may omit repeat biopsy. Upfront MRI with targeted and perilesional sampling may also remove the need for a separate confirmatory biopsy.
Apply it
A fit man with Grade Group 1 cancer chooses surveillance. Agree on scheduled PSA and biopsy assessment; a concerning PSA rise triggers investigation rather than automatic curative treatment.
Common pitfall: Stable MRI alone does not routinely replace biopsy. Biopsy exceptions require the specified favourable findings and continued monitoring.
38.When is watchful waiting different from active surveillance?
Watchful waiting usually adopts a symptom-directed, palliative intention when competing mortality or limited life expectancy makes curative treatment unlikely to provide meaningful benefit. For asymptomatic localised prostate cancer, life expectancy below ten years usually favours watchful waiting; above ten years, suitable low-risk disease generally favours active surveillance. This is an individual health assessment, not an age cutoff. Active surveillance preserves a curative pathway through structured reassessment. Follow-up during watchful waiting is individualised, including earlier assessment when progression could soon cause symptoms.
Apply it
A frail man with substantial competing illness and estimated life expectancy below ten years has asymptomatic localised cancer. Discuss watchful waiting rather than repeated biopsies without a realistic curative intention.
Common pitfall: Calling every untreated cancer 'surveillance' obscures the treatment goal. Reassess life expectancy, health and preferences as circumstances change.
39.What distinguishes bladder carcinoma in situ from a low-risk papillary tumour?
Bladder carcinoma in situ is a flat, high-grade urothelial malignancy confined to the mucosa and classified as Tis. Its lack of invasion does not imply low biological risk, and its flat appearance may make white-light recognition difficult. A low-grade papillary Ta tumour differs in architecture and grade as well as risk. Describe stage and grade explicitly rather than using 'superficial' as though all non-muscle-invasive disease shared the same clinical behaviour.
Apply it
Biopsy of an erythematous bladder patch shows high-grade malignant cells confined to the urothelium without invasion. Identify Tis carcinoma in situ and explain why the absence of a papillary mass does not make the finding benign.
Common pitfall: Non-invasive and low-grade are not synonyms. A flat mucosal lesion can be high-grade cancer even when it has not invaded underlying connective tissue.
40.Which tissue boundary separates T1 from T2 bladder cancer?
T1 bladder cancer invades subepithelial connective tissue, commonly termed lamina propria, while T2 invades muscularis propria. This distinction changes the disease category and management pathway. The pathology report must identify which muscle layer is involved because muscularis mucosae is not equivalent to detrusor muscle. Adequate resection and clearly identified detrusor tissue support staging confidence; a specimen lacking the relevant layer cannot establish that a deeper tumour component is absent elsewhere.
Apply it
A resection shows lamina propria invasion, with uninvolved muscularis propria separately identified. Classify the sampled tumour as T1 rather than T2, while considering the repeat-resection requirement and the possibility of residual or understaged disease.
Common pitfall: The word 'muscle' without anatomical identification can mislead. Muscularis mucosae involvement and muscularis propria invasion do not represent the same tumour stage.
EAU NMIBC — Pathological Staging and Classification Systems · EAU NMIBC — Diagnosis
41.When is repeat transurethral bladder tumour resection needed?
Repeat TURBT addresses residual tumour and inaccurate initial staging. It is indicated after incomplete resection or doubt about completeness, for T1 disease, and when detrusor muscle is absent except in specified situations such as Ta low-grade tumours and primary CIS. When indicated, the EAU recommends a second resection within two to six weeks, including the original tumour site. A visually complete first procedure does not remove the repeat-resection indication for a T1 tumour.
Apply it
A high-grade T1 tumour appears completely removed, and detrusor muscle is present and uninvolved. Arrange repeat TURBT because T1 itself remains an indication, using the second procedure to assess residual disease and confirm staging.
Common pitfall: Presence of muscle improves specimen quality but does not cancel every repeat-resection indication. Conversely, absent muscle in low-grade Ta disease is a recognised exception.
42.How should positive cytology with normal cystoscopy be investigated?
Positive urine cytology can reflect high-grade urothelial malignancy that is flat, inconspicuous or outside the visible bladder. A normal white-light cystoscopy therefore does not complete the evaluation. Investigate the upper urinary tract, assess the bladder for CIS using mapping or photodynamic-guided biopsies as appropriate, and sample the prostatic urethra when indicated. Cytology signals a need to locate a source; it does not independently establish which anatomical site contains the lesion.
Apply it
A man has repeatedly positive high-grade cytology but no visible bladder tumour. Plan upper tract evaluation and assessment for occult bladder CIS and prostatic urethral involvement instead of labelling the result irrelevant because cystoscopy looked normal.
Common pitfall: Do not assume the bladder must be the source of malignant urinary cells. Equally, normal bladder imaging cannot exclude a flat mucosal lesion.
43.Why is partial nephrectomy preferred for suitable T1 renal tumours?
Partial nephrectomy removes the tumour while preserving uninvolved renal tissue. For suitable T1 renal cell cancers, it provides effective cancer control with better preservation of kidney function than removing the whole kidney. Its functional importance increases with pre-existing chronic kidney disease, a solitary kidney or bilateral disease. Technical complexity and perioperative risks still matter, so feasibility requires individual assessment. A normal contralateral kidney does not by itself negate the value of conserving nephrons.
Apply it
A patient with chronic kidney disease has a technically resectable 3 cm renal cortical tumour. Discuss partial nephrectomy as the preferred surgical approach when feasible, balancing local operative risks against avoidable loss of functioning renal tissue.
Common pitfall: Radical surgery is not automatically oncologically superior for every small renal tumour. Conversely, nephron preservation should not justify an operation that cannot safely control the tumour.
44.When can the ipsilateral adrenal gland be preserved during nephrectomy?
Ipsilateral adrenalectomy should be driven by evidence of adrenal involvement rather than performed routinely with renal cancer surgery. Preoperative imaging and intraoperative findings guide the decision. An upper-pole location alone does not reliably predict adrenal invasion and does not independently mandate removal. Preserving an uninvolved gland avoids an unnecessary associated procedure while maintaining appropriate oncological surgery. Distinguish direct or metastatic adrenal involvement from simple anatomical proximity to the renal mass.
Apply it
A patient requires radical nephrectomy for an upper-pole tumour, but adrenal imaging is normal and there is no operative suspicion of involvement. Preserve the adrenal rather than removing it solely because of tumour location.
Common pitfall: Proximity is not invasion. Conversely, apparently routine preservation should not override a suspicious adrenal lesion or clear intraoperative evidence that the gland is involved.
45.Why does a significant AFP elevation challenge a diagnosis of pure seminoma?
Pure seminoma does not account for a significant tumour-related alpha-fetoprotein elevation. When pathology suggests seminoma but AFP is substantially elevated, consider an unsampled non-seminomatous component and review alternative causes of the marker abnormality. Seminoma can elevate hCG, so hCG and AFP have different discriminating roles. Interpret the magnitude and trend rather than treating every modest stable abnormality as definitive evidence of mixed germ-cell cancer. Histology and markers must be reconciled before classification.
Apply it
An orchidectomy report describes seminoma, but AFP is markedly elevated without an identified hepatic explanation. Seek specialist pathology and marker review for a non-seminomatous component rather than proceeding on the assumption that pure seminoma explains both findings.
Common pitfall: Do not apply the same interpretation to hCG: seminoma may elevate it. A small stable AFP elevation also requires context rather than automatic reclassification.
46.How should tumour markers be interpreted after orchidectomy?
AFP, hCG and LDH are measured before orchidectomy and reassessed afterward to support staging and prognosis. Marker decline takes time: AFP has a serum half-life of approximately five to seven days and hCG approximately one to three days. Persistently elevated or rising values can suggest residual or metastatic disease, but interpretation must consider expected decay and other causes. Normalisation does not exclude metastases, so marker trends complement rather than replace anatomical staging.
Apply it
A patient's AFP remains elevated two days after orchidectomy but is falling appropriately from a high baseline. Continue serial interpretation using its half-life and complete staging rather than declaring treatment failure from a single early postoperative result.
Common pitfall: Early persistence is not necessarily pathological persistence. Conversely, normal markers do not prove that all disease has been removed or that imaging is unnecessary.
Andrology, infertility and genital surgerynot stated
47.When should suspected testicular torsion proceed to urgent exploration?
Sudden severe unilateral scrotal pain, nausea or vomiting and an abnormal testicular lie should raise strong suspicion of torsion. Twisting the spermatic cord compromises perfusion, making assessment and treatment time-critical. Doppler can assist when promptly available, but persistent arterial flow does not exclude early, partial or intermittent torsion. Strong clinical suspicion warrants urgent surgical assessment and exploration without an avoidable imaging delay. Symptom improvement alone also does not securely establish that the threat has resolved.
Apply it
An adolescent has abrupt pain, vomiting and a high-riding horizontal testis. A scan would require a prolonged transfer. Arrange urgent exploration through the appropriate surgical pathway rather than waiting for imaging to confirm a compelling clinical diagnosis.
Common pitfall: Detectable arterial flow can falsely reassure. A partially twisted cord may preserve some flow while the clinical presentation still requires urgent intervention.
48.Why should an abnormal semen analysis be repeated?
Semen parameters vary biologically and are affected by collection and laboratory conditions. An abnormal baseline analysis should therefore be assessed with at least two consecutive semen analyses using appropriate WHO methods. A single result does not fully classify the cause of infertility or determine a couple's reproductive potential. Integrate repeated findings with history, examination and directed hormonal or genetic investigation. Apparent azoospermia also requires appropriate examination of the centrifuged specimen before concluding that sperm are absent.
Apply it
An infertile couple presents after one incomplete semen collection shows a low sperm count. Arrange a properly collected repeat assessment and evaluate both partners rather than making an irreversible treatment recommendation from that isolated result.
Common pitfall: Reference limits are not a binary boundary between fertility and sterility. Repeat results clarify a pattern but still require interpretation within the couple's circumstances.
49.Which genetic assessment follows congenital absence of the vas deferens?
Congenital absence of the vas deferens, especially bilateral absence with low-volume acidic azoospermia, suggests an obstructive phenotype associated with CFTR variants. Genetic testing and counselling inform the diagnosis and reproductive risk, including assessment of the partner before assisted reproduction. Finding sperm for intracytoplasmic injection does not remove the possibility of transmitting a genetic condition. Renal anatomy also deserves consideration, particularly with unilateral absence or when the genetic findings do not explain the phenotype.
Apply it
A man with azoospermia, small acidic ejaculate volume and bilaterally absent vasa requests immediate sperm retrieval. Arrange CFTR assessment and couple-based genetic counselling before assisted reproduction, while evaluating associated anatomy and realistic treatment options.
Common pitfall: Successful sperm retrieval solves an access problem, not an inheritance problem. Do not bypass partner assessment simply because testicular sperm production appears preserved.
50.Why are nitrates incompatible with PDE5 inhibitors?
PDE5 inhibitors reduce breakdown of cyclic GMP, while nitrates and other nitric oxide donors increase its production. Combining these effects can cause excessive vasodilation and unpredictable, potentially severe hypotension. Concomitant use is contraindicated, including recreational nitrites and the nitric oxide-donating drug nicorandil. A medication history must therefore include intermittent and recreational exposures. Stable cardiovascular disease alone is a different issue; the specific nitrate interaction cannot be dismissed because angina is currently controlled.
Apply it
A man requesting sildenafil uses glyceryl trinitrate intermittently and considers it unimportant because he rarely needs it. Identify the contraindication, explain the shared cyclic-GMP pathway and discuss suitable alternatives without instructing him to stop necessary cardiac treatment himself.
Common pitfall: Occasional nitrate use still matters. Taking a smaller PDE5 inhibitor dose does not establish safe concurrent use or remove the underlying pharmacodynamic interaction.
EAU Sexual and Reproductive Health — Management of Erectile Dysfunction
51.How do examination and hormones help classify azoospermia?
Azoospermia describes absent sperm in the ejaculate, not a single mechanism. Obstruction can coexist with preserved spermatogenesis, often suggested by normal-sized testes, relatively normal reproductive hormones or an identifiable ductal abnormality. Impaired sperm production may instead reflect primary testicular or hypothalamic-pituitary dysfunction. Confirm the semen finding and combine testicular examination, vasal assessment, hormones and directed genetic testing. Neither a normal FSH nor an isolated examination finding conclusively establishes the presence or absence of sperm production.
Apply it
One azoospermic man has normal-sized testes and absent vasa; another has small testes and elevated FSH. Use these contrasting patterns to guide investigation and counselling rather than assuming that both need the same reconstructive operation.
Common pitfall: Azoospermia is not synonymous with testicular failure. Equally, normal hormones do not guarantee normal spermatogenesis or make a complete infertility evaluation unnecessary.
Paediatric urologynot stated
52.When should orchidopexy be completed for an undescended testis?
Persistent undescended testes require timely correction because prolonged abnormal position is associated with loss of germ-cell potential. Once spontaneous descent is unlikely after early infancy, treatment should proceed with orchidopexy ideally between six and twelve months and by eighteen months at the latest. Prematurity requires attention to corrected age. Early successful surgery supports fertility potential but does not guarantee normal future fertility or erase all long-term risks, so counselling and later awareness remain important.
Apply it
A term infant still has a palpable inguinal testis at seven months. Arrange surgical management within the recommended early window rather than continuing observation until school age in the hope that late spontaneous descent will occur.
Common pitfall: A painless undescended testis is not a reason to delay. Earlier correction improves the opportunity to preserve function without guaranteeing a normal adult outcome.
53.How is a retractile testis distinguished from an undescended testis?
A retractile testis has completed descent but is drawn upward by an active cremasteric reflex. It can be brought into the scrotum and remains there at least temporarily without persistent tension, usually with normal size and consistency. This differs from a testis that cannot be positioned or maintained appropriately. Retractile testes generally need observation rather than immediate surgery, with yearly examination until puberty because secondary ascent can occur and changes the management category.
Apply it
A child's testis is initially suprascrotal but can be gently placed in the dependent scrotum and remains after release. Explain retractility and arrange annual examination, documenting position so future ascent can be recognised promptly.
Common pitfall: Being able to pull a testis briefly downward does not by itself prove retractility. Persistent tension or immediate return raises concern for a different position abnormality.
54.Why does a negative ultrasound not settle a nonpalpable testis?
Ultrasound cannot reliably establish that a nonpalpable testis is absent. Clinical assessment and operative evaluation are central; examination under anaesthesia may identify a previously nonpalpable testis, and diagnostic laparoscopy can locate an intra-abdominal testis or establish the relevant anatomy. Management then depends on viability, position and vascular findings. Bilateral nonpalpable testes also require endocrine assessment, rather than being treated simply as two independent localisation problems with repeated negative scans.
Apply it
An infant has a unilateral nonpalpable testis and an ultrasound report stating that no testis was seen. Arrange specialist operative assessment rather than reassuring the family that absence has been proved or ordering serial localisation scans.
Common pitfall: Failure to visualise is not evidence of anatomical absence. A scan should not postpone definitive assessment or obscure the separate significance of bilateral nonpalpable testes.
55.How should a newborn with suspected posterior urethral valves be stabilised?
Suspected neonatal infravesical obstruction requires prompt bladder drainage and antibiotic prophylaxis, alongside assessment of renal function, electrolytes, infection and overall stability. Prophylaxis aims to prevent infection; established infection requires therapeutic antibiotics. Voiding cystourethrography evaluates suspected posterior urethral valves. Endoscopic valve ablation follows drainage and stabilisation when feasible. If the child is too small for safe instrumentation, maintain temporary transurethral or suprapubic drainage. Consider upper tract diversion when bladder drainage is inadequate or clinical improvement fails.
Apply it
A newborn boy has bladder distension, bilateral upper tract dilatation and renal impairment. Drain, give prophylaxis and correct biochemical instability; obtain VCUG and plan ablation according to stability and instrument feasibility.
Common pitfall: Improved urine output does not remove the need for diagnostic confirmation. Prophylactic dosing does not adequately treat established infection.
EAU Paediatric Urology — Congenital Lower Urinary Tract Obstruction
56.Why is follow-up lifelong after posterior urethral valve ablation?
Valve ablation relieves the anatomical obstruction but cannot necessarily reverse established renal dysplasia or bladder dysfunction. Patients remain at risk of deteriorating renal function, abnormal storage and incomplete emptying as they grow. Follow-up therefore evaluates both kidneys and bladder, with management adapted to the evolving functional problem. The serum creatinine nadir provides prognostic information, but no single reassuring early measurement replaces ongoing monitoring. Transition to adult care is part of protecting long-term renal health.
Apply it
A school-aged boy had successful neonatal valve ablation but now has worsening wetting and rising creatinine. Reassess bladder function, emptying and renal status rather than assuming the absence of recurrent valves means the urinary tract is safe.
Common pitfall: Anatomical success is not the same as functional cure. Discharging a child after a satisfactory postoperative stream can miss progressive bladder and renal consequences.
EAU Paediatric Urology — Congenital Lower Urinary Tract Obstruction
Traumanot stated
57.Which test evaluates suspected male urethral injury after trauma?
In a stable male trauma patient, blood at the meatus, difficulty voiding or a relevant pelvic injury should prompt assessment for urethral disruption. Retrograde urethrography is a standard early investigation; flexible cystourethroscopy is an alternative in appropriate circumstances. Contrast extravasation identifies injury, although urethrography does not always reliably separate complete from partial disruption. Life-threatening injuries and resuscitation take priority. Avoid repeated forceful blind catheter attempts that may worsen injury or create a false passage.
Apply it
A haemodynamically stable man has a pelvic fracture, meatal blood and inability to void. Obtain retrograde urethrography or appropriate endoscopic assessment before repeated catheter attempts, then select drainage according to the demonstrated injury and overall trauma plan.
Common pitfall: The male imaging pathway should not be copied indiscriminately to female urethral injury, where cystourethroscopy and vaginoscopy are the preferred diagnostic assessments.
58.How must cystography be performed to exclude traumatic bladder rupture?
Visible haematuria with a pelvic fracture is an indication for cystography. CT or conventional cystography must actively fill the bladder retrogradely with adequate dilute contrast; the EAU specifies 300–350 mL in adults. Passive excretory filling during an ordinary contrast CT can leave the bladder insufficiently distended and miss rupture. The contrast distribution also distinguishes intraperitoneal from extraperitoneal leakage, directly informing treatment. A routine trauma CT without active bladder filling is not an equivalent exclusion test.
Apply it
A stable adult has a pelvic fracture and gross haematuria, but the routine contrast CT report describes no bladder leak. Arrange properly distended retrograde cystography because passive filling on the earlier scan cannot reliably exclude rupture.
Common pitfall: The presence of intravenous contrast in the bladder does not establish adequate cystography. Adult filling volumes should also not be transferred automatically to children.
59.Why does blunt intraperitoneal bladder rupture require repair?
Blunt intraperitoneal rupture commonly involves the bladder dome and releases urine into the peritoneal cavity. Ongoing leakage can cause peritonitis, intra-abdominal sepsis and serious physiological disturbance, so surgical exploration and repair are recommended. Inspect for associated intra-abdominal injury and provide urinary drainage. This mechanism differs from selected small uncomplicated intraperitoneal perforations during endoscopic procedures, which may permit conservative treatment in carefully defined circumstances. The injury's cause and associated findings determine whether that exception applies.
Apply it
After a blow to a full bladder, a patient has cystographic contrast outlining bowel loops. Arrange operative repair for blunt intraperitoneal rupture rather than assuming that catheter drainage alone will adequately control the intraperitoneal urine leak.
Common pitfall: Do not generalise conservative management of selected endoscopic perforations to external blunt trauma. Similar contrast locations can occur in clinically different injury settings.
60.When does extraperitoneal bladder rupture need surgery?
An uncomplicated blunt extraperitoneal bladder rupture can usually heal with continuous bladder drainage and observation. Surgery becomes necessary when the injury involves the bladder neck, trapped bladder wall, bone fragments within the wall or associated rectal or vaginal injury. These features impair healing or create additional contamination and functional risks. Other planned surgery can also influence repair decisions. Classify the injury's complexity explicitly rather than using the word extraperitoneal as an automatic instruction for nonoperative care.
Apply it
Cystography shows an extraperitoneal leak after pelvic trauma, and imaging demonstrates a bone fragment embedded in the bladder wall. Recommend operative management because this is a complicated rupture despite the absence of intraperitoneal contrast.
Common pitfall: Location is only the first branch of the decision. Catheter-only care is appropriate for uncomplicated extraperitoneal injury, not every rupture outside the peritoneal cavity.
What to focus on during revision
The following are CertMedbry study suggestions. Use the official outline to check the full scope of your examination.
- Use the complete 2026 ETR as the scope map; these 60 concepts are a selective starting point across all ten domains.
- Separate urgent source control from definitive treatment in infected obstruction, suspected torsion and transplant vascular complications.
- Practise BOOI, BCI and PSA-density calculations, stating what each result can and cannot establish.
- Connect autonomic receptor physiology, cellular preservation injury and renal-failure assessment to clinical decisions.
- Distinguish symptom improvement from progression prevention, continence from safe storage and anatomical correction from functional recovery.
- Apply treatment-aware PSA interpretation, life-expectancy assessment and structured surveillance criteria in prostate cancer decisions.
- Link cancer stage, grade, specimen adequacy and treatment intention before choosing the next investigation or intervention.
- Compare look-alike presentations using decisive cues: acute versus chronic prostatitis, obstructive versus non-obstructive azoospermia, and uncomplicated versus complicated bladder rupture.
A practical preparation plan
1. Map the full specialist scope
Read the ten knowledge sections of the 2026 ETR and mark areas beyond this guide, including broader basic science, renal failure and dialysis, oncological treatment, reconstruction, infections and operative competencies. Build a study schedule from that full scope without assigning invented examination percentages.
2. Build decision chains
For each presentation, state the likely mechanism, the dangerous alternative, the discriminating investigation and the next management step. Start with infected hydronephrosis, acute scrotum, graft anuria, positive cytology and pelvic trauma.
3. Calculate and interpret
Work through fresh BOOI, BCI, PSA-density and treatment-adjusted PSA examples without notes. Check units and timing of measurements, then explain the limitation of each calculation rather than stopping at the numerical answer.
4. Read the clinical recommendations in context
Use the cited EAU chapters and relevant ethics or infectious disease guidance to understand recommendation boundaries. Pay particular attention to exceptions involving asymptomatic bacteriuria, repeat TURBT, prostate surveillance biopsies, negative prostate MRI and traumatic bladder injury.
5. Complete the independent question set
Answer all 20 questions before reading explanations. For every distractor, identify the finding that would have made it appropriate. Record errors as mechanism, interpretation, management or boundary errors; use the result to direct revision.
6. Rehearse explanations and revisit gaps
Use the flashcards for spaced recall and give a brief spoken justification for each answer. Explain patient priorities, uncertainty and follow-up alongside clinical decisions, then return to the full ETR and current textbooks to broaden coverage.
Use your sample score as a starting point
The free set contains 20 original practice questions. It is a small learning sample, not an official examination or a validated pass prediction. Review each explanation and its source before moving to another topic.
Start the free sampleOfficial sources and updates
- EBU — Fellow of the EBU (FEBU)
- EBU — FEBU Part 1 Written Exam
- EBU — European Training Requirements
- European Training Requirements in Urology — Version 2026, UEMS 2026.16
- WMA International Code of Medical Ethics
- EAU Non-neurogenic Male LUTS — Diagnostic Evaluation
- IDSA 2019 Guideline on Asymptomatic Bacteriuria
- EAU Urological Infections — The Guideline
- EAU Non-neurogenic Male LUTS — Disease Management
- EAU Non-neurogenic Female LUTS — Disease Management
- EAU Neuro-urology — The Guideline
- EAU Renal Transplantation — The Guideline
- EAU Urolithiasis — Guidelines
- EAU Urolithiasis — Metabolic Evaluation and Recurrence Prevention
- EAU Prostate Cancer — Treatment
- EAU Prostate Cancer — Diagnostic Evaluation
- EAU NMIBC — Pathological Staging and Classification Systems
- EAU NMIBC — Diagnosis
- EAU Renal Cell Carcinoma — Disease Management
- EAU Testicular Cancer — Diagnostic Evaluation
- EAU Paediatric Urology — Acute Scrotum
- EAU Sexual and Reproductive Health — Male Infertility
- EAU Sexual and Reproductive Health — Management of Erectile Dysfunction
- EAU Paediatric Urology — Management of Undescended Testes
- EAU Paediatric Urology — Congenital Lower Urinary Tract Obstruction
- EAU Urological Trauma — Urogenital Trauma Guidelines
- UEMS — European Training Requirements
- Important information Part 1 Written Exam | EBU
- FEBU Part 2 Oral Exam | EBU
Confirm current eligibility, fees, scheduling and policies directly with the examination provider. CertMedbry is independent and is not endorsed by these organisations. How we handle content and corrections.